Altimmune Future Growth

Future criteria checks 2/6

Altimmune is forecast to grow earnings and revenue by 18.7% and 82.5% per annum respectively. EPS is expected to grow by 28.8% per annum. Return on equity is forecast to be -48.2% in 3 years.

Key information

18.7%

Earnings growth rate

28.8%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	82.5%
Future return on equity	-48.2%
Analyst coverage	Good
Last updated	14 Nov 2024

Recent future growth updates

Recent updates

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 13

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Earnings and Revenue Growth Forecasts

NasdaqGM:ALT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	0	-176	-96	-91	8
12/31/2025	22	-102	-78	-8	9
12/31/2024	0	-96	-78	-83	9
9/30/2024	0	-104	-78	-78	N/A
6/30/2024	0	-101	-71	-71	N/A
3/31/2024	0	-93	-73	-73	N/A
12/31/2023	0	-88	-76	-76	N/A
9/30/2023	0	-78	-77	-77	N/A
6/30/2023	0	-81	-71	-71	N/A
3/31/2023	0	-85	-69	-68	N/A
12/31/2022	0	-85	-63	-63	N/A
9/30/2022	3	-87	-67	-67	N/A
6/30/2022	3	-97	-70	-70	N/A
3/31/2022	4	-102	-80	-72	N/A
12/31/2021	4	-97	-91	-78	N/A
9/30/2021	3	-84	-82	-70	N/A
6/30/2021	6	-68	-74	-61	N/A
3/31/2021	7	-60	-54	-50	N/A
12/31/2020	8	-49	-35	-34	N/A
9/30/2020	6	-43	-23	-23	N/A
6/30/2020	4	-36	-16	-16	N/A
3/31/2020	5	-22	-12	-12	N/A
12/31/2019	6	-21	-10	-10	N/A
9/30/2019	8	-42	-13	-13	N/A
6/30/2019	10	-34	-12	-11	N/A
3/31/2019	11	-40	-8	-8	N/A
12/31/2018	10	-42	-10	-9	N/A
9/30/2018	11	-29	-10	-9	N/A
6/30/2018	13	-58	N/A	-12	N/A
3/31/2018	13	-52	N/A	-20	N/A
12/31/2017	11	-51	N/A	-20	N/A
9/30/2017	9	-43	N/A	-17	N/A
6/30/2017	5	-16	N/A	-15	N/A
3/31/2017	3	-14	N/A	-8	N/A
12/31/2016	3	-11	N/A	-6	N/A
9/30/2016	3	-10	N/A	-7	N/A
12/31/2015	5	-7	N/A	-5	N/A
12/31/2014	6	-1	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALT's revenue (82.5% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ALT's revenue (82.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALT is forecast to be unprofitable in 3 years.

Altimmune Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 11% to US$21.29

Consensus revenue estimates decrease by 29%

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Price target decreased by 11% to US$26.25

Price target decreased by 11% to US$26.25

Recent updates

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 29%

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Price target decreased by 11% to US$26.25

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 11% to US$26.25

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Independent Director exercised options and sold US$248k worth of stock

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Reassessing Altimmune

Altimmune sets new 52-week high on rising volume

Consensus forecasts updated

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Price target increased to US$24.86